Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Depression stories

Oct 15, 2026

UK antidepressant labels to add boxed warnings on suicide risk and sexual dysfunction

The UK Medicines and Healthcare products Regulatory Agency will strengthen antidepressant safety warnings with boxed alerts on suicidal thoughts and behaviors and sexual dysfunction, with patient cards expected in medicine packs.

Oct 15, 2026·2 sources
00
Oct 14, 2026

Compass Pathways CEO says company will 'go slow before we go fast' ahead of FDA submission

Compass Pathways CEO Kabir Nath stated the psychedelics company will take a measured approach as it prepares to complete submission of its psychedelic therapy for FDA regulatory review this quarter. The announcement comes as the company joins mental health organizations to mark the first U.S. Treatment-Resistant Depression Awareness Day.

Oct 14, 2026·3 sources
00
Oct 4, 2026

Lancet study links children's screen time to public health crisis

A new series of research papers published in The Lancet warns that excessive screen time among children and young adults poses a significant public health risk, with studies linking digital media use to millions of years of depression globally. Researchers are calling for regulation of tech companies' addictive design features rather than relying solely on parental controls.

Oct 4, 2026·6 sources
00
Sep 21, 2026

Derek Owusu's The Recovery House offers honest portrayal of mental health

The Guardian reviews Derek Owusu's new work The Recovery House, praising it as a uniquely honest exploration of mental health that draws unexpected connections, including references to the Cranberries' 1994 song Zombie.

Sep 21, 2026·1 source
00

FDA grants breakthrough therapy designation for DT120 ODT in depression treatment

The FDA has granted breakthrough therapy designation to Definium Therapeutics' DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder.

Sep 21, 2026·1 source
00
Sep 18, 2026

Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways executives revealed plans to model their upcoming psychedelic treatment launch after Johnson & Johnson's strategy for Spravato, the ketamine nasal spray, as the FDA considers approval. The move comes as psychedelic therapeutics face a critical juncture following Lykos' failed MDMA therapy approval in 2024.

Sep 18, 2026·2 sources
00
Sep 17, 2026

Xenon Pharmaceuticals pauses depression drug trials over neuropsychiatric side effects

Xenon Pharmaceuticals temporarily halted new patient enrollment in clinical studies of its experimental depression drug following reports of mental health-related adverse events, causing shares to fall.

Sep 17, 2026·3 sources
00
Aug 7, 2026

Study Reveals How Early-Life Stress Leaves Molecular 'Scar' in Brain Cells

Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.

Aug 7, 2026·4 sources
00

Study Reveals How Early-Life Stress Leaves Molecular 'Scar' in Brain Cells

Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.

Aug 7, 2026·5 sources
00

Clinical trial links ketamine's rapid anti-suicidal effects to morning cortisol surge

A recent clinical trial found that a single dose of ketamine increases morning cortisol levels in suicidal patients for up to 24 hours, potentially explaining the drug's rapid antidepressant and anti-suicidal effects. The finding adds to understanding of ketamine's therapeutic mechanisms beyond its original use as an anesthetic.

Aug 7, 2026·4 sources
00
Aug 6, 2026

UK's First Publicly Funded Trial Shows Psilocybin Significantly Improves Treatment-Resistant Depression

A randomized controlled trial conducted through the NHS in England found that a single dose of psilocybin, the active compound in magic mushrooms, produced significant improvements in depression symptoms among 60 adults with treatment-resistant major depressive disorder compared to placebo, with good tolerability.

Aug 6, 2026·4 sources
00
Aug 4, 2026

Wearable Technology Advances Mental Health Monitoring with New Fingertip Sensors and AI Integration

Researchers demonstrate fingertip sensors can identify physical patterns linked to stress, anxiety and depression, while major wearable companies including Whoop, Oura, and Apple expand into healthcare applications. Amae Health partners with Google Health to integrate Fitbit and voice biomarkers for precision psychiatry.

Aug 4, 2026·3 sources
00
Jul 31, 2026

MD Anderson researchers identify shared neuroimmune mechanisms in rapid-acting antidepressants

Scientists at The University of Texas MD Anderson Cancer Center have discovered common neuroimmune signatures that may explain how rapid-acting antidepressants like ketamine and psychedelics work to reduce symptoms in treatment-resistant depression.

Jul 31, 2026·1 source
00
Jul 7, 2026

Compass Pathways' Psilocybin Therapy Shows Durable Benefits for Treatment-Resistant Depression in Pivotal Trial

Compass Pathways reported results from a pivotal study showing its psilocybin-based therapy demonstrated long-lasting benefits for treatment-resistant depression, though investor reaction was mixed as shares fell nearly 10% on the data.

Jul 7, 2026·2 sources
00
Jun 22, 2026

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.

Jun 22, 2026·2 sources
00
May 23, 2026

Global Mental Health Disorders Affect 1.2 Billion People, Nearly Double Since 1990

A new study found that nearly 1.2 billion people had a mental disorder in 2023, representing a 95.5% increase since 1990, highlighting a significant global mental health crisis.

May 23, 2026·1 source
00
May 8, 2026

Kennedy Health Officials Explore U.S. Ban on Certain SSRI Antidepressants

Health officials under Robert F. Kennedy Jr. explored banning certain SSRI antidepressants as part of plans to reduce their use in the United States, sparking significant debate over medication safety and federal regulatory authority.

May 8, 2026·1 source
00
Apr 23, 2026

Scientists Identify Brain Cells Linked to Depression for the First Time

Researchers identify specific brain cell types and neural circuits linked to depression, offering new insight into underlying biology and potential targets for more precise treatments.

Apr 23, 2026·2 sources
00
Apr 16, 2026

Doctors and Patients Report Emotional Blunting Side Effect from GLP-1 Drugs, Dubbed 'Ozempic Personality'

Medical professionals and patients on social media are increasingly reporting a phenomenon called 'Ozempic personality,' characterized by emotional flattening and reduced ability to experience joy while taking GLP-1 medications for weight loss.

Apr 16, 2026·2 sources
00
Apr 6, 2026

Antidepressant Shows Promise in Reducing Methamphetamine Use

A new study demonstrates that a common antidepressant helps people cut back on methamphetamine use, offering potential treatment option for highly addictive stimulant.

Apr 6, 2026·1 source
00

Top claims

  • ▪The UK Medicines and Healthcare products Regulatory Agency announced updated safety warnings for all 28 authorised antidepressants, introducing boxed warnings on suicidal thoughts and behaviours in patient information leaflets
  • ▪The Commission on Human Medicines review into antidepressant safety was initiated after patients and families raised concerns regarding the communication of suicidal thoughts and persistent sexual dysfunction risks
  • ▪The MHRA said Antidepressant leaflet wording will be amended to remove references to a chemical imbalance and describe drug function in line with current clinical understanding

People involved

Robert F. Kennedy Jr.

Subtopics

Mental Health & Wellbeing12Psychedelic clinical research & trials8Stress, Burnout & Well-being8Mental health7Drug Approval and Clinical Trials5Drug Policy, Pricing & Approval5Anxiety4Psychedelic policy & regulation4Brain health & dementia researchers3Ketamine3Psychedelic renaissance3Biomarkers & bloodwork testing2Epigenetics experts2Pharma2Psilocybin2Public healthcare2Suicide prevention2Trauma & PTSD2Treatment-resistant depression2Accelerated approval pathways1Addiction & recovery1AI assistants & chatbots1Clinical trials1Digital wellness & digital detox1

Related timelines

Iran War

209 stories

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories

Russia-Ukraine war

136 stories